GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Acacia Pharma Group PLC (LTS:0PNT) » Definitions » Piotroski F-Score

Acacia Pharma Group (LTS:0PNT) Piotroski F-Score : 0 (As of Jun. 11, 2024)


View and export this data going back to 2018. Start your Free Trial

What is Acacia Pharma Group Piotroski F-Score?

The zones of discrimination were as such:

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Acacia Pharma Group has an F-score of 4 indicating the company's financial situation is typical for a stable company.

The historical rank and industry rank for Acacia Pharma Group's Piotroski F-Score or its related term are showing as below:


Acacia Pharma Group Piotroski F-Score Historical Data

The historical data trend for Acacia Pharma Group's Piotroski F-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Acacia Pharma Group Piotroski F-Score Chart

Acacia Pharma Group Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21
Piotroski F-Score
Get a 7-Day Free Trial 4.00 2.00 3.00 4.00 4.00

Acacia Pharma Group Semi-Annual Data
Dec15 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21
Piotroski F-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3.00 2.00 4.00 - 4.00

How is the Piotroski F-Score calculated?

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Dec21) TTM:Last Year (Dec20) TTM:
Net Income was €-59.36 Mil.
Cash Flow from Operations was €-39.45 Mil.
Revenue was €1.03 Mil.
Gross Profit was €0.77 Mil.
Average Total Assets from the begining of this year (Dec20)
to the end of this year (Dec21) was (84.53 + 54.882) / 2 = €69.706 Mil.
Total Assets at the begining of this year (Dec20) was €84.53 Mil.
Long-Term Debt & Capital Lease Obligation was €24.69 Mil.
Total Current Assets was €27.63 Mil.
Total Current Liabilities was €7.30 Mil.
Net Income was €-27.52 Mil.

Revenue was €0.17 Mil.
Gross Profit was €0.15 Mil.
Average Total Assets from the begining of last year (Dec19)
to the end of last year (Dec20) was (16.802 + 84.53) / 2 = €50.666 Mil.
Total Assets at the begining of last year (Dec19) was €16.80 Mil.
Long-Term Debt & Capital Lease Obligation was €25.71 Mil.
Total Current Assets was €41.42 Mil.
Total Current Liabilities was €9.10 Mil.

*Note: If the latest quarterly/semi-annual/annual total assets data is 0, then we will use previous quarterly/semi-annual/annual data for all the items in the balance sheet.

Profitability

Question 1. Return on Assets (ROA)

Net income before extraordinary items for the year divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Acacia Pharma Group's current Net Income (TTM) was -59.36. ==> Negative ==> Score 0.

Question 2. Cash Flow Return on Assets (CFROA)

Net cash flow from operating activities (operating cash flow) divided by Total Assets at the beginning of the year.

Score 1 if positive, 0 if negative.

Acacia Pharma Group's current Cash Flow from Operations (TTM) was -39.45. ==> Negative ==> Score 0.

Question 3. Change in Return on Assets

Compare this year's return on assets (1) to last year's return on assets.

Score 1 if it's higher, 0 if it's lower.

ROA (This Year)=Net Income/Total Assets (Dec20)
=-59.36/84.53
=-0.70223589

ROA (Last Year)=Net Income/Total Assets (Dec19)
=-27.519/16.802
=-1.63784073

Acacia Pharma Group's return on assets of this year was -0.70223589. Acacia Pharma Group's return on assets of last year was -1.63784073. ==> This year is higher. ==> Score 1.

Question 4. Quality of Earnings (Accrual)

Compare Cash flow return on assets (2) to return on assets (1)

Score 1 if CFROA > ROA, 0 if CFROA <= ROA.

Acacia Pharma Group's current Net Income (TTM) was -59.36. Acacia Pharma Group's current Cash Flow from Operations (TTM) was -39.45. ==> -39.45 > -59.36 ==> CFROA > ROA ==> Score 1.

Funding

Question 5. Change in Gearing or Leverage

Compare this year's gearing (long-term debt divided by average total assets) to last year's gearing.

Score 0 if this year's gearing is higher, 1 otherwise.

Gearing (This Year: Dec21)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec20 to Dec21
=24.694/69.706
=0.35425932

Gearing (Last Year: Dec20)=Long-Term Debt & Capital Lease Obligation/Average Total Assets from Dec19 to Dec20
=25.708/50.666
=0.50740141

Acacia Pharma Group's gearing of this year was 0.35425932. Acacia Pharma Group's gearing of last year was 0.50740141. ==> This year is lower or equal to last year. ==> Score 1.

Question 6. Change in Working Capital (Liquidity)

Compare this year's current ratio (current assets divided by current liabilities) to last year's current ratio.

Score 1 if this year's current ratio is higher, 0 if it's lower

Current Ratio (This Year: Dec21)=Total Current Assets/Total Current Liabilities
=27.632/7.296
=3.7872807

Current Ratio (Last Year: Dec20)=Total Current Assets/Total Current Liabilities
=41.421/9.104
=4.54975835

Acacia Pharma Group's current ratio of this year was 3.7872807. Acacia Pharma Group's current ratio of last year was 4.54975835. ==> Last year's current ratio is higher ==> Score 0.

Question 7. Change in Shares in Issue

Compare the number of shares in issue this year, to the number in issue last year.

Score 0 if there is larger number of shares in issue this year, 1 otherwise.

Acacia Pharma Group's number of shares in issue this year was 98.402. Acacia Pharma Group's number of shares in issue last year was 73.58. ==> There is larger number of shares in issue this year. ==> Score 0.

Efficiency

Question 8. Change in Gross Margin

Compare this year's gross margin (Gross Profit divided by sales) to last year's.

Score 1 if this year's gross margin is higher, 0 if it's lower.

Gross Margin (This Year: TTM)=Gross Profit/Revenue
=0.768/1.029
=0.74635569

Gross Margin (Last Year: TTM)=Gross Profit/Revenue
=0.15/0.173
=0.86705202

Acacia Pharma Group's gross margin of this year was 0.74635569. Acacia Pharma Group's gross margin of last year was 0.86705202. ==> Last year's gross margin is higher ==> Score 0.

Question 9. Change in asset turnover

Compare this year's asset turnover (total sales for the year divided by total assets at the beginning of the year) to last year's asset turnover ratio.

Score 1 if this year's asset turnover ratio is higher, 0 if it's lower

Asset Turnover (This Year)=Revenue/Total Assets at the Beginning of This Year (Dec20)
=1.029/84.53
=0.01217319

Asset Turnover (Last Year)=Revenue/Total Assets at the Beginning of Last Year (Dec19)
=0.173/16.802
=0.01029639

Acacia Pharma Group's asset turnover of this year was 0.01217319. Acacia Pharma Group's asset turnover of last year was 0.01029639. ==> This year's asset turnover is higher. ==> Score 1.

Evaluation

Piotroski F-Score= Que. 1+ Que. 2+ Que. 3+Que. 4+Que. 5+Que. 6+Que. 7+Que. 8+Que. 9
=0+0+1+1+1+0+0+0+1
=4

Good or high score = 7, 8, 9
Bad or low score = 0, 1, 2, 3

Acacia Pharma Group has an F-score of 4 indicating the company's financial situation is typical for a stable company.

Acacia Pharma Group  (LTS:0PNT) Piotroski F-Score Explanation

The developer of the system is Joseph D. Piotroski is relatively unknown accounting professor who shuns publicity and rarely gives interviews.

He graduated from the University of Illinois with a B.S. in accounting in 1989, received an M.B.A. from Indiana University in 1994. Five years later, in 1999, after earning a Ph.D. in accounting from the University of Michigan, he became an associate professor of accounting at the University of Chicago.

In 2000, he wrote a research paper called "Value Investing: The Use of Historical Financial Statement Information to Separate Winners from Losers" (pdf).

He wanted to see if he can develop a system (using a simple nine-point scoring system) that can increase the returns of a strategy of investing in low price to book (referred to in the paper as high book to market) value companies.

What he found was something that exceeded his most optimistic expectations.

Buying only those companies that scored highest (8 or 9) on his nine-point scale, or F-Score as he called it, over the 20 year period from 1976 to 1996 led to an average out-performance over the market of 13.4%.

Even more impressive were the results of a strategy of investing in the highest F-Score companies (8 or 9) and shorting companies with the lowest F-Score (0 or 1).

Over the same period from 1976 to 1996 (20 years) this strategy led to an average yearly return of 23%, substantially outperforming the average S&P 500 index return of 15.83% over the same period.


Acacia Pharma Group Piotroski F-Score Related Terms

Thank you for viewing the detailed overview of Acacia Pharma Group's Piotroski F-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Acacia Pharma Group (LTS:0PNT) Business Description

Traded in Other Exchanges
N/A
Address
Royston Road, The Officers’ Mess, Duxford, Cambridge, GBR, CB22 4QH
Acacia Pharma Group PLC is a biopharmaceutical company that focuses on developing and commercializing novel products to improve the care of patients undergoing medical treatments such as surgery, invasive procedures, or chemotherapy. Its product portfolio includes BARHEMSYS, BYFAVO, and APD403.

Acacia Pharma Group (LTS:0PNT) Headlines

No Headlines